Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 1;9(1):3199.
doi: 10.1038/s41598-019-39840-9.

Development of T cell immunity to norovirus and rotavirus in children under five years of age

Affiliations

Development of T cell immunity to norovirus and rotavirus in children under five years of age

Maria Malm et al. Sci Rep. .

Abstract

Most of the research effort to understand protective immunity against norovirus (NoV) has focused on humoral immunity, whereas immunity against another major pediatric enteric virus, rotavirus (RV), has been studied more thoroughly. The aim of this study was to investigate development of cell-mediated immunity to NoV in early childhood. Immune responses to NoV GI.3 and GII.4 virus-like particles and RV VP6 were determined in longitudinal blood samples of 10 healthy children from three months to four years of age. Serum IgG antibodies were measured using enzyme-linked immunosorbent assay and production of interferon-gamma by peripheral blood T cells was analyzed by enzyme-linked immunospot assay. NoV-specific T cells were detected in eight of 10 children by the age of four, with some individual variation. T cell responses to NoV GII.4 were higher than those to GI.3, but these responses were generally lower than responses to RV VP6. In contrast to NoV-specific antibodies, T cell responses were transient in nature. No correlation between cell-mediated and antibody responses was observed. NoV exposure induces vigorous T cell responses in children under five years of age, similar to RV. A role of T cells in protection from NoV infection in early childhood warrants further investigation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Norovirus (NoV)- and rotavirus (RV)-specific serum immunoglobulin G (IgG) end-point titers. Sera were titrated with 2-fold serial dilutions and IgG antibodies were analyzed against NoV GI.3 (a), NoV GII.4 (b) and RV VP6 (c) in enzyme-linked immunosorbent assay. Shown are end-point titers at the age of 3, 6 and 12 months, mean end-point titers at 2–3 years and 4 years of age. The horizontal line indicates geometric mean titer. Statistical differences were determined using Fisher’s exact test, and a p value of ≤0.05 was considered statistically significant (*). Each symbol denotes an individual child (▲ = Subject 1, ♦ = 2, ○ = 3, □ = 4, ×  = 5, Δ = 6, • = 7, ◊ = 8, ■ = 9, * = 10).
Figure 2
Figure 2
Norovirus (NoV)- and rotavirus (RV)-specific interferon gamma (IFN-γ) production by T cells. Peripheral blood mononuclear cells (PBMC) were stimulated o/n with NoV GI.3 (a) and GII.4 (b) VLPs and RV VP6 (c) (30 µg/ml each) and cytokine production analyzed by enzyme-linked immunospot (ELISPOT) assay. Due to the shortage of cells, PBMCs collected at the age of 6 and 12 months and 2 and 3 years were pooled. Shown are mean IFN-γ spot-forming cells (SFC)/106 PBMCs of two replicate wells of an individual sample. The horizontal line indicates the mean of the age grouped samples. The dashed line represents the positivity cut off (≥26 SFC/106 PBMCs). Statistical differences between the groups were determined by a Mann-Whitney U test, and a p value of ≤0.05 was considered statistically significant.

References

    1. Riera-Montes M, O’Ryan M, Verstraeten T. Norovirus and Rotavirus Disease Severity in Children: Systematic Review and Meta-analysis. Pediatr Infect Dis J. 2018;37:501–505. doi: 10.1097/INF.0000000000001824. - DOI - PubMed
    1. Payne DC, Parashar UD, Lopman BA. Developments in understanding acquired immunity and innate susceptibility to norovirus and rotavirus gastroenteritis in children. Curr Opin Pediatr. 2015;27:105–109. doi: 10.1097/MOP.0000000000000166. - DOI - PMC - PubMed
    1. Patel M, Glass R, Desai R, Tate JE, Parashar UD. Fulfilling the promise of rotavirus vaccines: how far have we come since licensure? Lancet Infect Dis. 2012;12:561–570. doi: 10.1016/S1473-3099(12)70029-4. - DOI - PubMed
    1. Nurminen K, et al. Prevalence of norovirus GII-4 antibodies in Finnish children. J Med Virol. 2011;83:525–531. doi: 10.1002/jmv.21990. - DOI - PubMed
    1. Leroux-Roels G, et al. Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial. J Infect Dis. 2018;217:597–607. doi: 10.1093/infdis/jix572. - DOI - PMC - PubMed

Publication types